Jonathan E. Kolitz, MD

Associate Investigator, The Feinstein Institute for Medical Research

Associate Chief, Hematologic Oncology, Monter Cancer Center

Professor of Medicine, Hofstra Northwell School of Medicine

Phone: (516) 734-8970
Email: kolitz@northwell.edu

About the Investigator

Dr. Jonathan Kolitz is a graduate of Columbia University and Yale School of Medicine.  He underwent postgraduate training in internal medicine, hematology and medical oncology at North Shore University Hospital and Memorial Sloan-Kettering Cancer Center.  

Dr. Kolitz currently is in charge of the hematologic malignancies program at Northwell Health’s Monter Cancer Center. He also has a large clinical practice and is involved in the education of fellows and house officers.

In addition, Dr. Kolitz is a professor of medicine at the Hofstra Northwell School of Medicine.

Education

Columbia University
Degree: BA
1975
Field of Study: Biological Sciences

Yale University School of Medicine
Degree: MD
1979
Field of Study: Medicine

Appointments

Academic Appointments:
1985 Research Assoc., Sloan-Kettering Institute for Cancer Research, NY
1985 Instructor in Medicine, Cornell University Medical College, NY
1991-1996 Asst. Prof. Of Medicine, Cornell University Medical College, NY
1996-2005 Asst. Prof. Of Medicine, New York University School of Medicine, NY
2005-2010 Associate Professor of Medicine, New York University School of Medicine, New York, NY
2009- 2010 Associate Professor of Medicine, Hofstra Northwell School of Medicine
2010-present Professor of Medicine, Hofstra Northwell School of Medicine

Hospital Appointments:
1985-1990 Clinical Asst. Physician, Hematology/Lymphoma Service, Dept. of Medicine,
Memorial Sloan Kettering Cancer Center, New York, NY
1990-1992 Provisional Medical Staff, Don Monti Division of Medical Oncology/Hematology,
Dept. of Medicine, North Shore University Hospital, Manhasset, NY
1992-1993 Asst. Attending Physician, Don Monti Division of Medical Oncology/Hematology,
Dept. of Medicine, North Shore University Hospital, Manhasset, NY
1993-1995 Senior Asst. Attending Physician, Don Monti Division of Medical Oncology/Hematology,
Dept. of Medicine, North Shore University Hospital, Manhasset, NY
1995-1999 Assoc. Attending Physician, Don Monti Division of Medical Oncology/Hematology, Dept.
of Medicine, North Shore University Hospital, Manhasset, NY
1995-1999 Associate Attending Physician, Don Monti Division of Oncology, Division of Hematology,
Department of Medicine, North Shore University Hospital, Manhasset, NY
1999-present Attending Physician, Don Monti Division of Oncology, Division of Hematology,
Department of Medicine, North Shore University Hospital, Manhasset, NY.
2000-2011 Director, Leukemia Service, Don Monti Division of Oncology, Division of Hematology,
Department of Medicine, North Shore University Hospital, Manhasset, NY.
2011-present Associate Chief, Hematologic Oncology, Monter Cancer Center,
Northwell Health, Lake Success, NY.

Publications
  1. Kolitz, J.E., George, S.L., Marcucci, G, Vij, R., Powell, B.L., Allen, S.L., Deangelo, D.J., Shea, T.C., Stock, W., Baer, M.R., Hars, V., Maharry, K., Hoke, E., Vardiman, J.W., Bloomfield, .CD., Larson, R.A. “P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.” Blood 2010, 116:1413-1421.
  2. Schwind, S., Maharry, K., Radmacher, M.D., Mrózek, K., Holland, K.B., Margeson, D., Whitman, S.P., Hickey, C., Becker, H., Metzeler, K.H., Paschka, P., Baldus, C.D., Liu, S., Garzon, R., Powell, B.L., Kolitz, J.E., Carroll, A.J., Caligiuri, M.A., Larson, R.A., Marcucci, G., Bloomfield, C.D.: “Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.” J. Clin Oncol. 2010, 28:5257-5264.
  3. Feldman, E.J., Lancet, J.E., Kolitz J.E., Ritchie, E.K., Roboz, G.J., List, A.F., Allen, S.L., Asatiani, E., Mayer, L.D., Swenson, C., Louie, A.C.. “First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.” J Clin Oncol. 2011, 29(8):979-985.
  4. Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrózek, K., Margeson, D., Becker, H.,Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.Z., Blum, W., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O.,, Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A,. Caligiuri, M.A., Marcucci, G., Bloomfield, C.D. “TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.” J Clin Oncol. 2011, 29:1373-1381.
  5. Yan, X.J,. Dozmorov, I., Li, W., Yancopoulos, S., Sison, C., Centola, M., Jain, P., Allen, S.L., Kolitz, J.E., Rai, K.R., Chiorazzi ,N, Sherry, B.: “Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.” Blood 2011, 118:5201-5210.
  6. Metzeler, K.H., Becker, H., Maharry, K., Radmacher, M.D., Kohlschmidt, J., Mrozek, K., Nicolet, D., Whitman, S.P., Wu, Y.Z., Schwind, S., Powell, B.L., Carte, T.H., Wetzler. M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G., Bloomfield, C.D.: “ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN “favorable” genetic category.” Blood, 2011 118:6920-6929.
  7. Cortes, J., Kantarjian, H., Ball, E.D., Dipersio, J., Kolitz, J.E., Fernandez, H.F., Goodman, M, Borthakur, G., Baer, M.R., Wetzler, M.: “Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.” Cancer. 2012, 118:418-427.
  8. Jain, P., Javdan, M., Feger, F.K., Chiu, P.Y., Sison, C., Damle, R.N., Bhuiya, T.A., Sen, F, Abruzzo, L.V., Burger, J.A., Rosenwald, A., Allen, S.L., Kolitz, J.E., Rai, K.R., Chiorazzi, N,, Sherry, B.: “Th17 and non-Th17 IL-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.” Haematologica. 2012, 97:599-607.
  9. Feldman, E.J., Kolitz, J.E., Trang, J.M., Liboiron, B.D., Swenson, C.E., Chiarella, M.T., Mayer, L.D., Louie, A.C., Lancet, J.E.: “Pharmacokinetics of CPX-351: a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin in patients with advanced leukemia.” Leuk. Res. 2012, PMID 22840315. July 26. [Epub ahead of print].
  10. Damle RN, Temburni S, Banapour T, Paul S, Mongini PK, Allen SL, Kolitz JE, Rai KR, Chiorazzi N. “T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.” Blood. 2012 Sep 20;120(12):2438-49.

View more at PubMed